NOVEL COMBINATION CHEMOTHERAPY FOR HODGKIN'S DISEASE (HD) IN HIV-INFECTED INDIVIDUALS (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

NOVEL COMBINATION CHEMOTHERAPY FOR HODGKIN'S DISEASE (HD) IN HIV-INFECTED INDIVIDUALS (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A7 1991. Unique Identifier : AIDSLINE ICDB/91671339
Kaplan L; Kahn J; Northfelt D; Abrams D; Volberding P; Univ. of California, San Francisco, CA 94110

Abstract: Five previously untreated HIV-seropositive men with histologically diagnosed HD were treated with bleomycin 10 U/m2 iv day 1; vincristine 1.4 mg/m2 iv day 1; streptozocin 750 mg/m2 iv day 1, 3, 5; and etoposide 100 mg/m2 iv day 1, 3, 5. Aerosolized pentamidine, 300 mg/mo was administered for P carinii prophylaxis. HIV risk group included homosexual (3), iv drug user (1), homosexual iv drug user (1). Mean age was 33 and no patient (pt) had a prior CDC-defined AIDS diagnosis. The median pretreatment CD4-positive lymphocyte count was 278/mm3 (range, 120-2110). Histologic pattern was nodular sclerosis in 3 and mixed cellularity in 2. Pretreatment staging with CT and bone marrow biopsy revealed Stage III disease in 2 and Stage IV in 3. Extranodal sites included bone marrow (1), liver (1), bone marrow and liver (1). Twenty-eight of a planned 30 cycles of chemotherapy were administered, all at full dose. The mean nadir neutrophil count for the group was 2050/mm3 (range 1.15-3.52). No cycle was complicated by fever and neutropenia. Toxicity included mild to moderate nausea in 4, transient severe peripheral neuropathy in 1, and transient moderate bilirubin elevation in 1. A self-limited episode of cryptosporidium diarrhea occurred in 1 pt. No other opportunistic infections occurred during therapy. Complete response occurred in 4 (80%) and partial response in 1 (20%). All remain alive at 5, 5, 6, 15, and 19 mo from diagnosis. These early results compare favorably with the poor response rates, short-survival times, severe myelosuppression and less than 50% dose intensity previously reported for similar pts receiving standard HD chemotherapy. This trial is ongoing.

Keywords: Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycin/ADMINISTRATION & DOSAGE Drug Administration Schedule Etoposide/ADMINISTRATION & DOSAGE Follow-Up Studies Hodgkin's Disease/*DRUG THERAPY/PATHOLOGY Human HIV Infections/*DRUG THERAPY HIV Seropositivity/DRUG THERAPY Male Neoplasm Staging Streptozocin/ADMINISTRATION & DOSAGE Vincristine/ADMINISTRATION & DOSAGE ABSTRACT

910830
M9181006

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .